Tag: @UCIrvine

DIETFITS: Identifying Groups with Varying Weight Loss Success

the most successful subgroup (73% met threshold) had high outcome expectations for making health improvements coupled with high levels of family encouragement

WeightControl.com Interview with:
Matthew J. Landry, PhD, RDN, FAND, FAHA (he/him)
Assistant Professor 
Department of Population Health & Disease Prevention 
University of California, Irvine 

WeightControl.com:  What is the background for this study? 

Response: Lifestyle interventions are the first-line treatment for obesity; however, not all participants achieve clinically significant weight loss.

As researchers and clinicians, we want to minimize patient burden, maximize clinical outcomes, and conserve constraints (budget & personnel).

Using data from a 12-month diet and weight loss intervention (DIETFITS), we examined 52 demographic, clinical, & psychosocial variables among 436 participants (BMI 28-40) to see if there are distinct subgroups of participants who were more or less successful in losing 5% weight by 12 months?

Continue reading “DIETFITS: Identifying Groups with Varying Weight Loss Success”

UCI Irvine Study Finds Millions May Benefit from Reduced Cardiac Events With New Weight Control Drugs

While the drug is costly to obtain by some patients, the cost savings associated with fewer doctor and hospital visits due to obesity and obesity-related diseases, in particular cardiovascular diseases (especially heart attacks, strokes, and heart failure) could be substantial.  

WeightControl.com Interview with:

Nathan D. Wong, PhD, FACC, FAHA
Professor and Director
Heart Disease Prevention Program
Division of Cardiology, UC Irvine and
and UC Irvine and Radiology and Public Health at UC Irvine

Nathan D. Wong, PhD, FACC, FAHA Professor and Director Heart Disease Prevention Program Division of Cardiology, UC Irvine and and UC Irvine and Radiology and Public Health at UC Irvine
Dr. Wong

WeightControl.com:  What is the background for this study? 

Response: Wegovy (semaglutide 2.4 mg given as an injection once weekly) has been shown in the previously reported STEP 1 trial to result in on average a 15% body weight loss in patients with overweight or obesity. It also beneficially improves other cardiovascular risk factors including blood pressure and cholesterol levels.   We applied the eligibility and findings of the STEP 1 trial to the US population-representative National Health and Nutrition Examination survey and estimated that 93 million US adults with overweight or obesity would be potentially eligible for the drug based on the STEP 1 eligibility criteria.  

Continue reading “UCI Irvine Study Finds Millions May Benefit from Reduced Cardiac Events With New Weight Control Drugs”